Screener
Sabra Healthcare SBRA Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Sabra Healthcare in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Sabra Healthcare’s 10-Q, filed April 29, 2026.
- Filed
- Apr 29, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001492298-26-000012
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Real estate investments, net of accumulated depreciation of $1,257,489 and $1,224,663 as of March 31, 2026 and December 31, 2025, respectively | $4,702,791 | $4,686,377 |
| Loans receivable and other investments, net | 432,909 | 434,100 |
| Investment in unconsolidated joint ventures | 116,537 | 118,166 |
| Cash and cash equivalents | 116,530 | 71,537 |
| Restricted cash | 6,921 | 6,603 |
| Lease intangible assets, net | 67,414 | 65,321 |
| Accounts receivable, prepaid expenses and other assets, net | 148,088 | 111,292 |
| Total assets | $5,591,190 | $5,493,396 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Sabra Healthcare's cash & equivalents?
- Sabra Healthcare (SBRA) reported cash & equivalents of $116.53M in Q1 2026.
- How has Sabra Healthcare's cash & equivalents changed year-over-year?
- Sabra Healthcare's cash & equivalents increased by 414.4% year-over-year, from $22.65M to $116.53M.
- What is the long-term trend for Sabra Healthcare's cash & equivalents?
- Over 5 years (2020 to 2025), Sabra Healthcare's cash & equivalents has grown at a 1.8% compound annual growth rate (CAGR), from $65.52M to $71.54M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Sabra Healthcare's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude